The formulation and an expanded indication for Tivicay tablets are currently under review in Europe The US Food and Drug Administration has approved the first-ever dispersible tablet formulation of ...

Dolutegravir is the first integrase inhibitor available as a dispersible tablet for oral suspension for children weighing at least 3kg and from four weeks of age. The FDA approval is testament to the ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved dolutegravir tablets and dolutegravir tablets for oral suspension to treat HIV infection, ...

Akums Drugs & Pharmaceuticals Ltd. has announced the launch of the world’s first Lasmiditan dispersible tablets, marking an important step forward in the treatment of acute migraine. The DCGI-approved ...

A new sweetened, cherry-flavoured dispersible antimalarial tablet is as effective as the crushed, currently used variety, which needs to be crushed before administration to small children, resulting ...

Otsuka is on course to further expand use of its treatment for pulmonary multidrug resistant tuberculosis (MDR-TB) to children. Europe's Committee for Medicinal Products for Human Use (CHMP) has ...

Children living with HIV have to take multiple different antiretroviral (ARV) pills or syrups twice a day, while most adults in South Africa have been offered one pill once a day regimen for around a ...

GPs have been advised to avoid prescribing effervescent, dispersible and soluble formulations of drugs after a study found they were associated with significantly increased risk of heart attacks and ...

ViiV Healthcare announces US FDA approval of the first-ever dispersible tablet formulation of dolutegravir, Tivicay PD, a once-daily treatment for children living with HIV Dolutegravir is the first ...